ADVERTISEMENT
Researchers at at VHIO in Barcelona, Spain, and Roche in Schlieren have presented a bi-specific antibody that prevents the side effects of HER2-targeting compounds.
Life Sciences venture capitalist Forbion has closed its new flagship fund, Forbion IV, at €360m, €90m above its original target of €250m.
Matured, diversified and willing to expand – this is how the Spanish biotech sector presented itself during BIOSPAIN 2018 in Seville. Andalusia has launched the first bioeconomy policy strategy in Spain.
Barcelona-based Minoryx Therapeutics announced during BIOSPAIN 2018 it has raised another €21.3m in a Series B financing bringing its assets to a total of €50M.
A team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells.
Cancer immunotherapy has been heralded as paradigm change in cancer treatment. Now, Roche’s US arm Genentech announced that the companys anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) improved survival by only two months as first-line treatment for patients with the rare lung cancer SCLC.
A new gene drive can cause the complete collapse of caged malaria-carrying mosquito populations, researchers from Imperial College report in Nature Biotechnology.
The CHMP elected Harald Enzmann as its new Chair on Friday, and recommended thirteen medicines for approval, three thereof orphan medicines.
European stock exchange operator Euronext kicked off its fourth annual capital markets training programme for non-listed companies – this time also including companies from Germany, Italy, Spain, and Switzerland.